3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside
BioMarin Pharmaceutical ($BMRN), Boston Scientific ($BSX), and Ionis Pharmaceuticals ($IONS) are three healthcare stocks with Strong Buy ratings an...
Biomarin Pharmaceutical Inc (BMRN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hudson Bay Capital Management Sander Gerber | 750,002 | $45,000,120 | -10% | 0.14% |
| 2. | Renaissance Technologies Jim Simons | 727,771 | $43,666,260 | +62% | 0.06% |
| 3. | Rhenman & Partners Asset Management Henrik Rhenman | 386,900 | $23,214,000 | +34% | 2.57% |
| 4. | Levin Easterly Partners John Murphy | 360,107 | $21,606,420 | +10% | 1.13% |
| 5. | 10,000,000 | $9,772,080 | 0.28% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.75 | 3,625 | $314,468.75 | 10,905 | 2022-10-31 | Filing | |
| $78.84 | 900 | $70,955.37 | 30,740 | 2020-08-31 | Filing | |
| $78.22 | 11,900 | $930,759.69 | 29,840 | 2020-08-31 | Filing | |
| $21.76 | 161 | $3,503.36 | 100,574 | 2012-10-31 | Filing | |
| $21.76 | 548 | $11,924.48 | 15,294 | 2012-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $66.28 | 17,557 | $1,163,748.19 | 61,003 | 2026-09-02 | Filing | |
| $53.85 | 3,281 | $176,681.85 | 51,818 | 2026-05-07 | Filing | |
| $60.46 | 16,486 | $996,743.56 | 79,953 | 2026-03-11 | Filing | |
| $60.38 | 6,326 | $381,937.31 | 37,578 | 2026-02-26 | Filing | |
| $61.36 | 26,061 | $1,599,102.96 | 72,453 | 2026-02-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,735,548 | $1,244,132,899 | 0.02% | |
| 2. | 14,988,996 | $899,339,760 | 0.56% | |
| 3. | 14,625,740 | $877,544,400 | 0.47% | |
| 4. | 8,723,746 | $523,424,760 | 0.01% | |
| 5. | 8,371,887 | $502,313,220 | 0.02% |
News See All
The Strategic Financial Case for BioMarin Pharmaceutical (BMRN)
TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the “TCW Relative Value Mid Cap Fund”. The letter can be downloaded here.
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
BioMarin Pharmaceutical Inc.
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
BioMarin Pharmaceutical Inc.
Ascendis Pharma Stock (ASND) Soars 7% on a Settlement with BioMarin Pharmaceutical (BMRN)
Ascendis Pharma stock rallied 7% on Monday after the company reached a global settlement and license deal with BioMarin Pharmaceutical.
BioMarin Pharmaceutical (BMRN)'s Alesta Deal Adds New Growth Potential in Rare Diseases
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expanding its rare-disease business with the acquisition of Alesta Therapeutics for $275 million upfront.
Q2 Earnings Blowouts: 37 Stocks That Beat Expectations
The ongoing earnings season has been a boon to listed companies' share prices in the second quarter of the year, helping offset macroeconomic uncertainties such as the US-Iran war, global trade, and questions...
10 Most Promising Stocks with Highest Upside Potential
In this article, we will discuss the 10 Most Promising Stocks with Highest Upside Potential.
10 Most Undervalued Stocks to Buy and Hold for 2 Years
In this article, we will discuss the 10 Most Undervalued Stocks to Buy and Hold for 2 Years.
8 Stocks That Could 10X by 2030
In this article, we will discuss the 8 Stocks That Could 10X by 2030.
Hedge Fund Resource Center